[go: up one dir, main page]

GB0708691D0 - Anticancer treatments a - Google Patents

Anticancer treatments a

Info

Publication number
GB0708691D0
GB0708691D0 GBGB0708691.1A GB0708691A GB0708691D0 GB 0708691 D0 GB0708691 D0 GB 0708691D0 GB 0708691 A GB0708691 A GB 0708691A GB 0708691 D0 GB0708691 D0 GB 0708691D0
Authority
GB
United Kingdom
Prior art keywords
anticancer treatments
anticancer
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0708691.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority to GBGB0708691.1A priority Critical patent/GB0708691D0/en
Publication of GB0708691D0 publication Critical patent/GB0708691D0/en
Priority to PCT/GB2008/050330 priority patent/WO2008135792A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0708691.1A 2007-05-04 2007-05-04 Anticancer treatments a Ceased GB0708691D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0708691.1A GB0708691D0 (en) 2007-05-04 2007-05-04 Anticancer treatments a
PCT/GB2008/050330 WO2008135792A1 (en) 2007-05-04 2008-05-06 Pm00104 compound for use in cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0708691.1A GB0708691D0 (en) 2007-05-04 2007-05-04 Anticancer treatments a

Publications (1)

Publication Number Publication Date
GB0708691D0 true GB0708691D0 (en) 2007-06-13

Family

ID=38198780

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0708691.1A Ceased GB0708691D0 (en) 2007-05-04 2007-05-04 Anticancer treatments a

Country Status (2)

Country Link
GB (1) GB0708691D0 (en)
WO (1) WO2008135792A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102065865B (en) * 2008-05-16 2013-03-20 马尔药品公司 Multiple myeloma treatments
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035842A1 (en) * 1999-05-14 2004-07-21 Pharma Mar Sa METHOD OF HEMISINTESIS FOR THE FORMATION OF INTERMEDIARY AND DERIVATIVE COMPOUNDS AND OF STRUCTURES RELATED TO ECTEINASCIDINE AND TETRAHYDROISOCHINOLINPHENOLS AND INTERMEDIARY APPLICATION COMPOUNDS IN SUCH METHOD
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations

Also Published As

Publication number Publication date
WO2008135792A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
GB0813916D0 (en) A Protection arrangement
EP2340752A4 (en) A bread-toaster
GB0908606D0 (en) A stereo-endoscope
PL2148561T3 (en) A planter
AP2010005191A0 (en) A structure
GB0820978D0 (en) A relief valve
GB0719518D0 (en) Therapy
GB0922260D0 (en) A pipe-liner
GB0821985D0 (en) A gear
PL2242399T3 (en) A footstool
IL208001A0 (en) Improved anticancer treatments
GB0708691D0 (en) Anticancer treatments a
GB0719788D0 (en) A retaining arrangement
GB2458284B (en) A button-cuff
GB0820625D0 (en) A medicament
PL2237716T3 (en) A diswasher
GB0808288D0 (en) A different windturbine
GB0710043D0 (en) Anticancer treatments
GB0708693D0 (en) Anticancer treatments
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0719860D0 (en) A combination therapy
GB0705557D0 (en) A treatment
GB0722047D0 (en) A medicament
PH32007000636S1 (en) A barstool

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)